clinical trial · NCT06450184
Bioequivalence Study of Pimavanserin 34 mg Capsule
Humanis Saglık Anonim Sirketi·phase1·completed·n = 32
Parkinson Disease PsychosisPimavanserin 34 mgNUPLAZID 34 MG Oral Capsule
brief summary
An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single dose bioequivalence study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in normal, healthy, adult, human subjects under fasting condition.
started
Jan 11, 2024
primary completion
Jan 17, 2024
completion
Mar 9, 2024
last updated
Jun 10, 2024
official title
An Open-label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Two Way Cross-over, Single Dose Bioequivalence Study of Pimavanserin 34 mg Capsule of Humanis Sağlık A.Ş., Turkey and NUPLAZID® (Pimavanserin) Capsules of Acadia Pharmaceuticals Inc. San Diego, CA 92130 USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol